Evidence map›Paper›PMID 41648036›Full record

ArticleESMO gastrointestinal oncology2024

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to

E B Faber, Y Baca, J Xiu, P Walker, G Manji, S Gholami, A Saeed, A Prakash, G P Botta, D Sohal and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

E B FaberDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis.
Y BacaCaris Life Sciences, Phoenix.
J XiuCaris Life Sciences, Phoenix.
P WalkerCaris Life Sciences, Phoenix.
G ManjiDivision of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York.
S GholamiNorthwell Health, New York.
A SaeedDivision of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh.
A PrakashDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis.
G P BottaDivision of Oncology, Department of Medicine, University of California-San Diego Health, La Jolla.
D SohalDepartment of Medicine, University of Cincinnati, Cincinnati.
H J LenzDivision of Medical Oncology, Department of Medicine, Keck School of Medicine at the University of Southern California, Los Angeles.
A F ShieldsBarbara Ann Karmanos Cancer Institute at Wayne State University, Detroit.
C NabhanCaris Life Sciences, Phoenix.
W El-DeiryDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, USA.
A SeeberDepartment of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck/Tirol Kliniken, Innsbruck, Austria.
V ChiuCedars-Sinai, The Angeles Clinic and Research Institute, Los Angeles, USA.
J HwangDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis.
E LouDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The majority of pancreatic ductal adenocarcinomas (PDACs) are driven by mutant (mt) Materials and methods: 4142 PDAC and 3727 colorectal cancer (CRC) cases with Results: We found Conclusions: Therapeutic IO targets like programmed death-ligand 1 are enriched in pancreatic adenocarcinoma cases harboring specific targetable variants of

Indexed as

genomicsKRASpancreatic adenocarcinomapancreatic cancertumor microenvironment

Identifiers

PMID41648036
PMCPMC12836609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.